Oncometabolic surgery in gastric cancer patients with type 2 diabetes

Yun Suk Choi*, Jin Wook Yi, Woo Young Shin & Yoonseok Heo

The rates of early gastric cancer and type 2 diabetes mellitus (T2DM) are sharply increasing in Korea. Oncometabolic surgery in which metabolic surgery is conducted along with cancer surgery is a method used to treat gastric cancer and T2DM in one-stage operation. From 2011 to 2019, a total of 48 patients underwent long-limb Roux-en-Y gastrectomy (LRYG) in Inha University Hospital, and all data were reviewed retrospectively. A 75 g oral glucose tolerance test and serum insulin level test were performed before and 1 week and 1 year after surgery. One year after LRYG operation, 25 of 48 patients showed complete or partial remission and 23 patients showed non-remission of T2DM. The preoperative HbA1c level was significantly lower and the change in HbA1c was significantly greater in the T2DM remission group. Insulin secretion indices (insulinogenic index and disposition index) were increased significantly in the T2DM remission group. In contrast, the insulin resistance indices (homeostatic model assessment of insulin resistance (HOMA-IR) and Matsuda index) changed minimal. In the case of LRYG in T2DM patients, remnant β cell function is an important predictor of favorable glycemic control.
Patients and methods
A retrospective study was conducted with 48 gastric cancer patients with T2DM who underwent LRYG at Inha University Hospital from January 2011 to December 2019. Of these 48 patients, 36 underwent subtotal gastrectomy, and 12 underwent total gastrectomy. Among these patients, laboratory tests, including oral glucose tolerance tests (OGTTs) and serum insulin levels were performed before and 1 week and 1 year after surgery. Based on these results, various DM indices were calculated and reviewed. The insulinogenic index and disposition index were used to evaluate the patients’ insulin secretory function, and the homeostatic model assessment of insulin resistance (HOMA-IR) and Matsuda index were used to evaluate the insulin resistance. The baseline and postoperative follow-up data, glycemic control status outcomes, antidiabetic medication use and success of T2DM remission were reviewed.

Analytic method. T2DM patients were defined as those with fasting blood sugar (FBS) > 126 mg/dL and HbA1c > 7% or those with a previous antidiabetic medication history. T2DM complete remission was defined as HbA1c < 6% and FBS < 100 mg/dL, and partial remission was defined as HbA1c < 6.5% and FBS 100–125 mg/dL without the use of antidiabetic medication 1 year after surgery. The non-remission group was defined as those who used antidiabetic medication or those whose glucose profile was not controlled to at least the partial remission level.

Surgical method. Oncometabolic surgery was performed only on patients expected to have stage I or II on preoperative examination, because these patients are expected long term survival and no need of chemotherapy. Radical D1+ or D2 subtotal gastrectomy or total gastrectomy was performed according to the patient’s gastric cancer location and stage. Conventional Roux-en-Y anastomosis is usually performed with a 20 cm jejunal limb and a 40 cm Roux limb. In contrast, for LRYG anastomosis, the jejunal limb was made 80 cm below the Treiz ligament for foregut bypassing, and a 80 cm Roux limb was made to perform anastomosis with the remnant stomach to reach the distal ileum early.

Statistical analysis. Statistical analysis was performed using SPSS v 22.0 (SPSS Inc., Chicago, IL). The chi-square test was used to analyze categorical variables, and Student’s t-test was used to analyze continuous variables in the T2DM and non-T2DM groups. Fisher’s exact test was used to analyze categorical variables, and the Mann–Whitney test was used to analyze continuous variables in the subtotal gastrectomy subgroup analysis. Data are presented as the means with standard deviations or medians with ranges.

Ethics. All patients were gastric cancer patients and they must perform gastrectomy. Oncometabolic surgery and OGTT were explained to all patients. Only patients who provided informed consent to oncometabolic surgery and OGTT were included and patients who did not want were excluded.

The study protocol was approved by the Institutional Review Board of Inha University Hospital (IRB number: INH 2021-01-013). All methods were performed in accordance with the relevant guidelines and regulations.

Results
Forty patients were using oral antidiabetic drugs; among them, 5 patients were using insulin injections as well. Eight patients did not use antidiabetic treatment. 6 patients were diagnosed with T2DM for the first time before surgery and 2 patients did not use voluntarily anti diabetic medication. The T2DM remission group included 25 patients (25/45, 55.6%), and the non-remission group included 23 patients. In the T2DM remission group, 21 patients (21/45, 46.7%) achieved complete remission, and 4 patients (4/45, 8.9%) achieved partial remission. In the non-remission group, 19 patients used oral antidiabetic drugs, 1 patient used insulin injection along with oral antidiabetic drugs, and 3 patients did not use antidiabetic drugs in spite of their HbA1c > 7.0% at 1 year although they have HbA1C level < 7.0% in laboratory at 6 month, because they refuse antidiabetic drugs.

Table 1 shows the clinical characteristics of these two groups. Preoperative HbA1c was significantly lower in the T2DM remission group (6.95 ± 1.06% vs. 7.95 ± 1.67%; p = 0.002). There was a more significant difference in HbA1c levels at 1 year after LRYG (5.75 ± 0.32% vs. 7.33 ± 1.04%; p = 0.001). T2DM duration was shorter in remission group, but it was not statistically significant. The preoperative insulinogenic index and disposition index, which represent insulin secretory function, were significantly higher in the T2DM remission group (0.28 ± 0.30 vs. 0.10 ± 0.12; p = 0.015, 0.81 ± 0.78 vs. 0.46 ± 0.39; p = 0.077). The preoperative insulin level was also significantly higher in the T2DM remission group (12.13 ± 7.78 vs. 8.44 ± 3.31; p = 0.041). After 1 year, serum insulin increased more in the T2DM remission group. Insulin secretory function improved 1 year after surgery, resulting in a larger difference between the two groups than that of previous ones. In the T2DM remission group, the insulin secretory indices 1 year after surgery improved to within the normal range. However, the non-remission group did not show significant improvement (Fig. 1).

Insulin resistance indices (HOMA-IR and Matsuda index) were rather high in the T2DM remission group. In both groups, they improved rapidly 1 week after surgery and worsened again 1 year after surgery, but the patients showed improved insulin resistance status compared with that before surgery. There was no statistically significant difference between the two groups. The body mass index (BMI) change between both groups 1 year after surgery was not statistically significant.

In the T2DM remission group, the OGTT results improved sharply 1 week after surgery and became almost normal after 1 year. Insulin secretion also increased to some extent in the non-remission group, and the OGTT results showed a similar pattern to that of the normal group, but the results were not in the normal range (Fig. 2).
Table 1. Clinical characteristics of patients included in this study (non-remission vs remission). T2DM Type 2 Diabetes Mellitus, BMI Body mass index, HOMA-IR Homeostatic model assessment of insulin resistance.

| Variable                        | Non-remission (n = 23) | Remission (n = 25) | p value |
|---------------------------------|------------------------|--------------------|---------|
| Mean age (years)                | 62.74 ± 9.5            | 58.72 ± 9.0        | 0.139   |
| Sex                             |                        |                    | 0.715   |
| Male                            | 17(81.0%)              | 23(85.2%)          |         |
| Female                          | 4(19.0%)               | 4(14.8%)           |         |
| T2DM duration                   | 8.39 ± 7.08            | 5.12 ± 6.13        | 0.093   |

**Preoperative diabetes medication**

| Variable                        | Non-remission (n = 23) | Remission (n = 25) | p value |
|---------------------------------|------------------------|--------------------|---------|
| No medication                   | 2(8.7%)                | 6(24.0%)           | 0.341   |
| Oral medication                 | 18(78.3%)              | 17(68.0%)          |         |
| Insulin injection               | 3(13.0%)               | 2(8.0%)            |         |
| BMI (kg/m²) - pre op            | 23.30 ± 3.51           | 22.64 ± 2.48       | 0.334   |
| BMI (kg/m²) - 1 year            | 22.33 ± 3.70           | 22.64 ± 2.48       | 0.740   |
| BMI change rate (%)             | 10.20 ± 10.06          | 12.38 ± 6.90       | 0.384   |
| Fasting glucose (mg/dL) - pre op| 123.87 ± 58.71         | 120.56 ± 33.66     | 0.814   |
| C-peptide (ng/dL) - fast - pre op| 1.79 ± 1.03           | 2.18 ± 1.66        | 0.337   |
| C-peptide (ng/dL) - fast – 1 year| 1.45 ± 0.84           | 1.66 ± 1.34        | 0.635   |
| Insulin (mIU/L) - fast - pre op | 8.44 ± 3.31            | 12.13 ± 7.78       | 0.041   |
| HbA1C (%) - pre op              | 7.95 ± 1.67            | 6.95 ± 1.06        | 0.02    |
| HbA1C (%) - 1 year               | 7.33 ± 1.04            | 5.75 ± 0.32        | 0.001   |
| HOMA-IR - pre op                | 2.71 ± 1.80            | 3.66 ± 2.78        | 0.181   |
| Matsuda index - pre op           | 6.30 ± 4.65            | 4.01 ± 3.46        | 0.070   |
| Insulinogenic index - pre op     | 0.10 ± 0.12            | 0.28 ± 0.30        | 0.015   |
| Disposition index - pre op       | 0.48 ± 0.39            | 0.81 ± 0.78        | 0.078   |

Figure 1. Diabetic index in long-limb Roux-en-Y gastrectomy patients (n = 48). *P value: preoperative versus 1-year postoperative value in the non-remission group. **P value: preoperative versus 1-year postoperative value in the remission group.
Among 48 patients, 36 underwent subtotal gastrectomy. Twenty patients improved and were included in the T2DM remission group, of whom 18 patients maintained their remission status, and 2 patients maintained partial remission status. Table 2 shows the clinical characteristics of the patients who underwent subtotal LRYG. Preoperative HbA1c was significantly lower in the T2DM remission group (6.76 ± 0.87% vs. 7.63 ± 1.43%; p = 0.045). In this group, the HbA1c level improved further, so there was a more significant difference in HbA1c after 1 year (5.75 ± 0.27% vs. 7.25 ± 1.17%; p = 0.002). T2DM duration was statistically significantly shorter in remission group (7.75 ± 6.48 vs. 4.10 ± 3.56; p = 0.039). The preoperative insulinogenic index and disposition index were significantly higher in the T2DM remission group (0.31 ± 0.32 vs. 0.13 ± 0.14; p = 0.038, 0.95 ± 0.83 vs. 0.50 ± 0.42; p = 0.057). The insulin resistance index and insulin secretory function index showed similar change patterns (Fig. 3).

Table 2. Clinical characteristics of patients included in the subtotal gastrectomy with long-limb Roux-en-Y bypass group (non-remission vs. remission). T2DM Type 2 Diabetes Mellitus, BMI Body mass index, HOMA-IR Homeostatic model assessment of insulin resistance.
Of the 12 patients who underwent total gastrectomy, 5 patients showed T2DM remission, of whom 3 showed remission status and 2 showed partial remission status. In the subtotal gastrectomy group, the proportion of patients with T2DM remission was high, but the difference was not statistically significant (20/36 (55.6%) vs. 5/12 (41.7%): *p* = 0.404).

Table 3 shows the preoperative factors associated with T2DM remission according to logistic regression. In the univariable analysis, there was no predictor associated with T2DM remission. After multivariable model selection, the preoperative insulinogenic index was the only significant predictor of T2DM remission (Odds ratio 133.831 (0.905–19,791.308), *p* = 0.045).

**Discussion**

T2DM is caused by an increase in insulin resistance. Insulin secretory function compensates for the increase in insulin resistance. However, if this compensation does not suffice, the glucose level becomes uncontrollable. If this hyperglycemic stress persists for a long time, pancreatic β cell function is eventually destroyed, resulting in a decrease in insulin secretion. Because Asian people have fewer pancreatic β cells, insulin secretion decreases more severely than in Western people.

The mechanism of gastric cancer surgery as a metabolic surgery has some similarity to that of bariatric RYG. Remnant stomach volume reduction through gastric resection results in caloric restriction and weight loss. In the case of Billroth II (BII) or Roux-en-Y gastrectomy, food material bypasses the duodenum and proximal

---

**Figure 3.** Diabetic index in subtotal long-limb Roux-en-Y gastrectomy patients (n = 36). *P value: preoperative versus 1-year postoperative value in the non-remission group. **P value: preoperative versus 1-year postoperative value in the remission group.

| Table 3. Factors associated with T2DM remission*. *Logistic regression model with backward selection. BMI Body mass index, HOMA-IR Homeostatic model assessment of insulin resistance. |
|---------------------------------------------------------------|
| **Univariable** | **Multivariable** |
| **Odds ratio (95% CI)** | **p value** | **Odds ratio (95% CI)** | **p value** |
| Age (years, mean ± sd) | 0.960 (0.871–1.057) | 0.365 | |  |
| Sex (reference: male) | 2.897 (0.290–28.912) | 0.365 | |  |
| BMI (kg/m²) | 1.192 (0.867–1.640) | 0.279 | |  |
| Gastrectomy type (reference: subtotal) | 0.587 (0.095–3.621) | 0.566 | |  |
| C-peptide—pre op | 0.966 (0.452–2.063) | 0.929 | |  |
| HOMA-IR—pre op | 1.114 (0.762–1.630) | 0.577 | |  |
| Matsuda index—pre op | 0.898 (0.683–1.178) | 0.437 | |  |
| Insulogenic index—pre op | 44.040 (0.000–4,484,018.395) | 0.520 | 133.831 (0.905–19,791.308) | 0.045 |
| Disposition index—pre op | 1.599 (0.027–95.561) | 0.822 | |  |
jejum due to the bypassing of the alimentary tract and reaches the distal ileum earlier than is the case in normal individuals. The difference is that gastric cancer patients are relatively less obese; therefore, the effect of weight loss is small compared to that in bariatric patients. In the case of subtotal gastrectomy, the fundus cannot be excised, which is disadvantageous in reducing caloric restriction and ghrelin secretion. The bypass length is shorter than that in bariatric surgery, therefore the effect of enteric hormonal changes may be weaker than that of bariatric RYGP.

The T2DM remission rate after conventional subtotal gastrectomy was reported to be 11.2—22.2%, and after Roux-en-Y reconstruction, it was reported to be 20—30.7%13,27,34—36. After LRYG, the remission rate is reported to be 11.6—78.6%24,25. In this study, the postoperative remission rate was approximately 47%, and when partial remission was included in this rate, it was approximately 55.6% 1 year after surgery. This remission rate is comparable to the T2DM remission rate in patients with class II obesity4,5,37. One of the reasons DM improves after bariatric RYGP is weight loss, which has the effect of improving insulin resistance. Another reason is the effect of changes in hormones at the insuloenteric axis, caused by the change in alimentary tract passing, which is contributes more than weight loss. The foregut hypothesis posits that patients undergoing duodenal bypass experience antidiabetic effects due to decreased anti-incretin factor. The hindgut hypothesis posits that early contact of food material with the distal ileum improves diabetes through the increased and early release of hormones such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY)17–21.

The improvement in T2DM after conventional gastrectomy has been thought to be caused by improved insulin resistance due to weight loss. However, in several previous bariatric studies or gastrectomy studies, there have been reports that pancreatic β cell function plays a more important role in T2DM remission38—40. In our study, the preoperative insulinogenic index, which represents insulin secretory function, was the only significant factor influencing T2DM remission. Insulin resistance showed a rapid improvement without weight loss within 1 week after surgery, after which it worsened. Insulin resistance and weight reduction did not show differences 1 year after surgery between the two groups. In contrast, insulin secretion showed a significant difference between both groups 1 year after surgery. In addition, the shape of OGTT graph of the non-remission group showed a normal one, but the glucose value was abnormal. These results indicated that the improvement in T2DM after LRYG caused by increased insulin secretion due to the effect of metabolic surgery was greater than the improvement caused by weight reduction, which is similar to the findings of studies conducted in obese T2DM patients21.

A statistically significant factor related to T2DM remission was the preoperative insulinogenic index. The preoperative insulinogenic index was a useful index (AUC = 0.694), and the insulinogenic index cutoff value was 0.105 (sensitivity = 0.609, specificity = 0.773). (Fig. 4) The normal value of the insulinogenic index is known to be 0.4 or higher; however, LRYG may be considered in patients with an insulinogenic index of 0.1 or higher.

The OGTT test is a very uncomfortable examination because it causes dizziness, nausea, vomiting, etc. It requires several blood samples at one visit, so patient compliance is poor. In this study, various diabetes indices were obtained through OGTT and serum insulin level tests. It is worthwhile to determine which factor is more important in the indication of T2DM remission by calculating the indices. The mixed meal tolerance test cannot calculate various DM indices. Although OGTT is an inconvenient test, it was used for the purpose of this study. All patients were given informed consent for oncometabolic surgery and OGTT test. This study was started in 2010. At the time, it was thought that a biliopancreatic limb and alimentary limb of about 80 cm would be
sufficient. Nowadays, longer limbs are accepted as the usual method. If it is performed with a longer biliopancreatic limb and alimentary limb, better results can be expected.

This study was a retrospective study, so the influence of selection bias cannot be excluded. There were some patients who missed follow-up visits, and there was difficulty performing the OGTT test, so some laboratory results were missing. Of the 58 patients, 10 had missing data, and 48 patients were included in the analyses. This study had only 1-year follow-up results and a small number of patients, which limited the statistical power. There is a lack of comparative evaluation of patients’ nutritional status.

The effects of LRYG on weight loss and insulin resistance improvement were not different between the two groups, and the difference in insulin secretory function was the most important factor associated with T2DM remission. The results of this study shows that the effect of LRYG in T2DM patients with low BMI was similar to that of metabolic surgery in obese T2DM patients. Onometabolic surgery can be one of the optional surgery for T2DM gastric cancer patients with a high possibility of long-term survival and well-preserved pancreatic β cell function, even if they are within normal weight. Besides, these results give us glimpses of the possibility for expanding the indication for metabolic surgery for the T2DM patients with over-weight or normal BMI.

Received: 14 December 2021; Accepted: 23 June 2022

References
1. Brethauer, S. A. et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann. Surg. 258, 628–637. https://doi.org/10.1097/SLA.0b013e3182a5034b (2013).
2. Cohen, R. V. et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 35, 1420–1428. https://doi.org/10.2337/dc11-2289 (2012).
3. Hall, T. C., Pellen, M. G., Sedman, P. C. & Jain, P. K. Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes. Surg. 20, 1245–1250. https://doi.org/10.1007/s11695-010-0198-8 (2010).
4. Mingrone, G. et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N. Engl. J. Med. 366, 1577–1585. https://doi.org/10.1056/NEJMoa120111 (2012).
5. Schauer, P. R. et al. Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann. Surg. 238, 467–485. https://doi.org/10.1097/SLA.0b013e318285411b (2003).
6. Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet (London, England) 387, 1513–1530. https://doi.org/10.1016/S0140-6736(16)30061-8 (2016).
7. Yoon, K. H. et al. Epidemic obesity and type 2 diabetes in Asia. Lancet (London, England) 368, 1661–1668. https://doi.org/10.1016/S0140-6736(06)69703-1 (2006).
8. Leon, J. Y. et al. Prevalence of diabetes and prediabetes according to fasting plasma glucose and HbA1c. Diabetes Metab. J. 37, 349–357. https://doi.org/10.4093/dmj.2013.37.3.349 (2013).
9. Ko, S. H. et al. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002–2013: Nationwide population-based cohort study. Medicine (Baltimore) 95, 4018. https://doi.org/10.1097/MD.0000000000004018 (2016).
10. American Diabetes, A. Economic costs of diabetes in the U.S. in 2012. Diabetes care 36, 1033-1046, doi:https://doi.org/10.2337/dc12-2625 (2013).
11. Shin, H.-Y. et al. Cause-of-death statistics in the Republic of Korea, 2014. J. Korean Med. Assoc. 59, 3-22 (2016).
12. Jin, D. C. Major changes and improvements of dialysis therapy in Korea: review of end-stage renal disease registry. Korean J. Intern. Med. 30, 17–22. https://doi.org/10.3904/kjim.2015.30.1.17 (2015).
13. Choi, K. S. et al. Effect of endoscopy screening on stage at gastric cancer diagnosis: Results of the National cancer screening programme in Korea. Br. J. Cancer 112, 608–612. https://doi.org/10.1038/bjc.2014.608 (2015).
14. Jun, J. K. et al. Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality. Gastroenterology 152, 1319-1328.e1317. https://doi.org/10.1053/j.gastro.2017.03.019 (2017).
15. Lee, W. et al. Comparative study of diabetes mellitus resolution according to reconstruction type after gastrectomy in gastric cancer patients with diabetes mellitus. Obes. Surg. 22, 1238–1243. https://doi.org/10.11695/os.011695-01-0580-1 (2012).
16. Peng, D., Cheng, Y.-X. & Zhang, W. Does Roux-en-Y construction really bring benefit of type 2 diabetes mellitus remission after gastrectomy in patients with gastric cancer? A systematic review and meta-analysis. Diabetes Ther. 11, 2863–2872. https://doi.org/10.1007/s13300-020-00934-7 (2020).
17. Bojsen-Moller, K. N. et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes 63, 1725–1737. https://doi.org/10.2337/db13-1307 (2014).
18. Cummings, D. E. et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. 346, 1623–1630. https://doi.org/10.1056/NEJMoa129008 (2002).
19. Drucker, D. J. The role of gut hormones in glucose homeostasis. J. Clin. Invest. 117, 24–32. https://doi.org/10.1172/JCI30076 (2007).
20. Nannipieri, M. et al. Roux-en-Y gastric bypass and sleeve gastrectomy: Mechanisms of diabetes remission and role of gut hormones. J. Clin. Endocrinol. Metab. 98, 4391–4399. https://doi.org/10.1210/jc.2013-2538 (2013).
21. Nannipieri, M. et al. The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J. Clin. Endocrinol. Metab. 96, E1372-E1379. https://doi.org/10.1210/jc.2011-0464 (2011).
22. Choi, Y. Y., Noh, S. H. & An, J. Y. A randomized controlled trial of Roux-en-Y gastrojejunostomy vs. gastroduodenostomy with respect to the improvement of type 2 diabetes mellitus after distal gastrectomy in gastric cancer patients. PloS One 12, e0188904. https://doi.org/10.1371/journal.pone.0188904 (2017).
23. Park, J. Y., Kwon, O. K., Jeon, J. H., Choi, Y. K. & Park, K. B. Impact of the different biliopancreatic limb length on diabetes and incretin hormone secretion following distal gastrectomy in gastric cancer patients. Sci. Rep. 11, 22451. https://doi.org/10.1038/s41598-021-02001-y (2021).
24. Kim, J. H. et al. Multicenter results of long-limb bypass reconstruction after gastrectomy in patients with gastric cancer and type II diabetes. Asian J. Surg. 43, 297–303. https://doi.org/10.1016/j.jassur.2019.03.018 (2020).
25. Kim, W. S., Kim, J. W., Ahn, C. W. & Choi, S. H. Resolution of type 2 diabetes after gastrectomy for gastric cancer with long limb Roux-en-Y reconstruction: A prospective pilot study. J. Korean Surg. Soc. 84, 88–93. https://doi.org/10.4174/jkss.2013.84.2.88 (2013).
26. Park, J. M., Kim, J. W. & Chi, K. C. Long-limb Roux-en-Y reconstruction after subtotal gastrectomy to treat severe digestive gastroparesis. J. Gastric Cancer 19, 365–371. https://doi.org/10.5230/jgc.2019.19.e23 (2019).
27. Kim, J. W., Cheong, J.-H., Hyung, W. J., Choi, S.-H. & Noh, S. H. Outcome after gastrectomy in gastric cancer patients with type 2 diabetes. World J. Gastroenterol. 18, 49–54. https://doi.org/10.3748/wjg.v18.i1.49 (2012).
28. Lee, T. H. et al. Long-term follow-up for type 2 diabetes mellitus after gastrectomy in non-morbidly obese patients with gastric cancer: The legitimacy of onco-metabolic surgery. *J. Gastric Cancer* **17**, 283–294. https://doi.org/10.5323/ijgc.2017.17.3.e34 (2017).
29. Liu, T., Xie, G. W., Tian, Q. Z. & Li, J. Radical gastrectomy combined with modified gastric bypass surgery for gastric cancer patients with type 2 diabetes. *Cell Biochem. Biophys.* **72**, 839–844. https://doi.org/10.1007/s12013-015-0546-3 (2015).
30. Zhu, Z. et al. Clinical course of diabetes after gastrectomy according to type of reconstruction in patients with concurrent gastric cancer and type 2 diabetes. *Obes. Surg.* **25**, 673–679. https://doi.org/10.1007/s11695-014-1428-4 (2015).
31. Caprio, S. The oral disposition index: A valuable estimate of β-cell function in obese youth. *J. Pediatr.* **161**, 3–4. https://doi.org/10.1016/j.jpeds.2012.02.013 (2012).
32. Matsuda, M. & DeFronzo, R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. *Diabetes Care* **22**, 1462–1470. https://doi.org/10.2337/diacare.22.9.1462 (1999).
33. Pacini, G. & Mari, A. Methods for clinical assessment of insulin sensitivity and beta-cell function. *Best Pract. Res. Clin. Endocrinol. Metab.* **17**, 305–322. https://doi.org/10.1016/s1521-6900(03)00042-3 (2003).
34. Ho, T. W. et al. Total gastrectomy improves glucose metabolism on gastric cancer patients: a nationwide population-based study. *Surg. Obes. Relat. Dis.* **12**, 635–641. https://doi.org/10.1016/j.soard.2015.11.024 (2016).
35. Kang, K. C., Shin, S. H., Lee, Y. J. & Heo, Y. S. Influence of gastrectomy for stomach cancer on type 2 diabetes mellitus for patients with a body mass index less than 30 kg/m(2). *J. Korean Surg. Soc.* **82**, 347–355. https://doi.org/10.4174/jkss.2012.82.6.347 (2012).
36. Kim, A. R. et al. Changes of quality of life in gastric cancer patients after curative resection: A longitudinal cohort study in Korea. *Ann. Surg.* **256**, 1008–1013. https://doi.org/10.1097/SLA.0b013e31827661c9 (2012).
37. Schauer, P. R. et al. Bariatric surgery versus intensive medical therapy for diabetes — 5-year outcomes. *N. Engl. J. Med.* **376**, 641–651. https://doi.org/10.1056/NEJMoa1600869 (2017).
38. Kwon, O., Lee, Y. J., Yu, J. H., Kim, M. S. & Heo, Y. The recovery of beta-cell function is critical for antidiabetic outcomes of gastric bypass in asian subjects with type 2 diabetes and a body mass index below 30. *Obes. Surg.* **27**, 541–544. https://doi.org/10.1007/s11695-016-2455-y (2017).
39. Lee, W. J. et al. Predicting success of metabolic surgery: Age, body mass index, C-peptide, and duration score. *Surg. Obes. Relat. Dis.* **9**, 379–384. https://doi.org/10.1016/j.soard.2012.07.015 (2013).
40. Still, C. D. et al. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: A retrospective cohort study. *Lancet Diabetes Endocrinol.* **2**, 38–45. https://doi.org/10.1016/j.cldiab.2013.03.003 (2014).
41. Zorrilla-Nunez, L. F. et al. Importance of the biliopancreatic limb length in gastric bypass: A systematic review. *Surg. Obes. Relat. Dis.* **15**, 43–49. https://doi.org/10.1016/j.soard.2018.10.013 (2019).

**Acknowledgements**

This research was funded by the Korea Disease Control and Prevention Agency. (Grant number 2020ER640301).

**Author contributions**

Conceptualization: Y.S.C., Data curation: Y.S.C., Formal analysis: Y.S.C., W.Y.S., Funding acquisition: Y.S.H., Investigation: Y.S.C., Methodology: Y.S.H., Project administration: Y.S.C., J.W.Y., Resources: Y.S.C., J.W.Y., Supervision: Y.S.H., Writing—original draft: Y.S.C., Writing—review & editing: Y.S.H.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Correspondence and requests for materials should be addressed to Y.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022